Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease - ...

Genentech announced a third round of layoffs, affecting 143 jobs, as part of its strategic workforce adjustments, amid broader job cuts across various sectors in Northern California.

Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...

The study, led from the University of Utah, analyzed 3,286 hospitals across the country, using data from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey, which ran ...

Reduced doses in antifibrotic therapy for patients with idiopathic pulmonary fibrosis did not significantly impact outcomes, ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

A fresh wave of layoffs is sweeping across Northern California, with job cuts spanning the biotech, retail, agriculture and health care sectors — signaling mounting economic pressures in the region.

Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...